Optimizing PBC Management: Emerging Therapies, Risk Stratification, and Patient-Centered Care

CAN-eng

$0

free

MOC - Section 3

30 min

Hepatology

1.5 Credits

Take this Course
LEARN MORE

Course Description

This is a 30-minute MOC Section 3 accredited eCME program for Canadian HCPs. This program provides evidence-based guidance on the management of primary biliary cholangitis (PBC), focusing on risk stratification, initiation of second-line therapy, and symptom management. Using a case-based approach, the program will explore strategies for timely treatment decisions, review evidence for second-line therapies (e.g., OCA, elafibranor), and highlight the importance of multidisciplinary collaboration to optimize patient-centered care.

This program has received financial support from Ipsen Biopharmaceuticals in the form of an unrestricted educational grant.

Course Details

Expiry Date: 2026-07-17
Professions: Specialist

Faculty

  • Gideon Hirschfield, MA(Oxon) MB BChir (Cantab) FRCP PhD
  • Tian Yan Chen, MD, FRCPC

Accreditation

This activity is a Self-Assessment (Section 3) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada, and approved by the Queen’s University CPD Team. You may claim a maximum of 1.5 hours (credits are automatically calculated). Session ID: 00018017

Learning Objectives

Upon completion of this continuing education program participants will be better able to:​

  • Recognize the burden of PBC and its impact on patient quality of life
  • Use risk stratification to guide timely treatment decisions and individualized patient care
  • Evaluate advancements in second-line therapies for PBC management, including efficacy and safety data
Take this Course